Influence of Neoadjuvant Radiation Dose on Patients Undergoing Esophagectomy and Survival in Locally Advanced Esophageal Cancer
- 114 Downloads
Neoadjuvant chemoradiotherapy followed by resection is standard of care for patients with locally advanced esophageal cancer, however, a significant portion of these patients do not undergo surgical intervention. This study evaluates radiation dose and other factors associated with undergoing esophageal resection and their impact on outcomes including survival.
Patients diagnosed with esophageal cancer between 2010 and 15 were queried from the National Cancer Database and stratified into low-dose radiation (41.4 Gy) (LDR) or high-dose radiation (50.0 or 50.4 Gy) (HDR) groups. Multivariable Logistic and Cox Regression analyses were performed to investigate the effect of multiple variables on the likelihood of undergoing esophagectomy and overall survival, respectively. Propensity score matching was performed to reduce bias between groups.
A total of 3633 patients met study criteria with 3005 (82.7%) undergoing esophagectomy. A greater proportion received HDR (3163 (87.1%)) than LDR (470 (12.9%)). The use of LDR increased from 4.7% (n = 22) in 2010 to 20.7% (n = 154) in 2015. Factors associated with undergoing esophagectomy included LDR, adenocarcinoma histology, and younger age. Radiation dosage did not impact overall survival, but undergoing esophagectomy was associated with improved survival. After propensity matching, a greater portion of the LDR group underwent esophagectomy (87.0 vs 81.1%, p = 0.013). There was no difference in R0 3 resection (93.2 vs 92.4%, p = 0.678) or complete pathologic response (19.3 vs 21.5%, p = 0.442) between LDR and HDR groups.
The use of LDR is increasing but still underutilized. LDR is associated with increased rates of esophagectomy without negatively impacting overall survival, R0 resection, or complete pathologic response.
KeywordsRadiation dosage Esophagectomy Esophageal cancer
Presented at Digestive Disease Week 2018, June 5, 2018, Washington DC.
Per the guidelines of the International Committee of Medical Journal Editors (ICMJE), all persons listed as authors meet all of the following criteria:
- Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work.
- Drafting the work or revising it critically for important intellectual content.
- Final approval of the version to be published.
- Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
- 1.Ferlay, J., I. Soerjomataram, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D.M. Parkin, D. Forman, and F. Bray, Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer, 2015. 136(5).Google Scholar
- 2.Noone AM, H.N., Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975–2015. Available from: https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER web site, April 2018.
- 4.Little, A.G., A.E. Lerut, D.H. Harpole, W.L. Hofstetter, J.D. Mitchell, N.K. Altorki, and M.J. Krasna, The Society of Thoracic Surgeons practice guidelines on the role of multimodality treatment for cancer of the esophagus and gastroesophageal junction. The Annals of Thoracic Surgery, 2014. 98(5): p. 1880–1885.CrossRefGoogle Scholar
- 5.Tepper, J., M.J. Krasna, D. Niedzwiecki, D. Hollis, C.E. Reed, R. Goldberg, K. Kiel, C. Willett, D. Sugarbaker, and R. Mayer, Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2008. 26(7): p. 1086.CrossRefGoogle Scholar
- 6.Khushalani, N.I., C.G. Leichman, G. Proulx, H. Nava, L. Bodnar, D. Klippenstein, A. Litwin, J. Smith, E. Nava, and L. Pendyala, Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. Journal of Clinical Oncology, 2002. 20(12): p. 2844–2850.CrossRefGoogle Scholar
- 7.Buckstein, M., R. Rhome, M. Ru, and E. Moshier, Neoadjuvant chemoradiation radiation dose levels for surgically resectable esophageal cancer: predictors of use and outcomes. Diseases of the Esophagus, 2017.Google Scholar
- 8.Herskovic, A., K. Martz, M. Al-Sarraf, L. Leichman, J. Brindle, V. Vaitkevicius, J. Cooper, R. Byhardt, L. Davis, and B. Emami, Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. New England Journal of Medicine, 1992. 326(24): p. 1593–1598.CrossRefGoogle Scholar
- 9.Minsky, B.D., T.F. Pajak, R.J. Ginsberg, T.M. Pisansky, J. Martenson, R. Komaki, G. Okawara, S.A. Rosenthal, and D.P. Kelsen, INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. Journal of clinical oncology, 2002. 20(5): p. 1167–1174.CrossRefGoogle Scholar
- 10.van Hagen, P., M. Hulshof, J. Van Lanschot, E. Steyerberg, M.V.B. Henegouwen, B. Wijnhoven, D. Richel, G. Nieuwenhuijzen, G. Hospers, and J. Bonenkamp, Preoperative chemoradiotherapy for esophageal or junctional cancer. New England Journal of Medicine, 2012. 366(22): p. 2074–2084.CrossRefGoogle Scholar
- 11.Cox, J.D. and K.K. Ang, Radiation Oncology E-Book: Rationale, Technique, Results. 2009: Elsevier Health Sciences.Google Scholar
- 12.Gunderson, L.L. and J.E. Tepper, Clinical Radiation Oncology, Fourth Edition. 2016, Philadelphia, PA: Elsevier.Google Scholar
- 13.Lin, S.H., K.W. Merrell, J. Shen, V. Verma, A.M. Correa, L. Wang, P.F. Thall, N. Bhooshan, S.E. James, and M.G. Haddock, Multi-institutional analysis of radiation modality use and postoperative outcomes of neoadjuvant chemoradiation for esophageal cancer. Radiotherapy and Oncology, 2017. 123(3): p. 376–381.CrossRefGoogle Scholar
- 14.Network, N.C.C., NCCN Esophageal Cancer Guidelines. 2016. 2017.Google Scholar
- 16.Kelsen, D.P., K.A. Winter, L.L. Gunderson, J. Mortimer, N.C. Estes, D.G. Haller, J.A. Ajani, W. Kocha, B.D. Minsky, and J.A. Roth, Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Journal of Clinical Oncology, 2007. 25(24): p. 3719–3725.CrossRefGoogle Scholar
- 20.Bedenne, L., P. Michel, O. Bouché, C. Milan, C. Mariette, T. Conroy, D. Pezet, B. Roullet, J.-F. Seitz, and J.-P. Herr, Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. Journal of clinical oncology, 2007. 25(10): p. 1160–1168.CrossRefGoogle Scholar
- 21.Stahl, M., M. Stuschke, N. Lehmann, H.-J. Meyer, M.K. Walz, S. Seeber, B. Klump, W. Budach, R. Teichmann, and M. Schmitt, Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. Journal of clinical oncology, 2005. 23(10): p. 2310–2317.CrossRefGoogle Scholar
- 22.Brower, J.V., S. Chen, M.F. Bassetti, M. Yu, P.M. Harari, M.A. Ritter, and A.M. Baschnagel, Radiation dose escalation in esophageal cancer revisited: a contemporary analysis of the National Cancer Data Base, 2004 to 2012. International Journal of Radiation Oncology• Biology• Physics, 2016. 96(5): p. 985–993.CrossRefGoogle Scholar
- 23.Kachnic, L.A., K. Winter, T. Wasserman, D. Kelsen, R. Ginsberg, T.M. Pisansky, J. Martenson, R. Komaki, G. Okawara, and S.A. Rosenthal, Longitudinal quality-of-life analysis of RTOG 94–05 (Int 0123): A Phase III trial of definitive chemoradiotherapy for esophageal cancer. Gastrointestinal cancer research: GCR, 2011. 4(2): p. 45.Google Scholar
- 24.Lee, H.K., A.A. Vaporciyan, J.D. Cox, S.L. Tucker, J.B. Putnam, J.A. Ajani, Z. Liao, S.G. Swisher, J.A. Roth, and W.R. Smythe, Postoperative pulmonary complications after preoperative chemoradiation for esophageal carcinoma: correlation with pulmonary dose–volume histogram parameters. International Journal of Radiation Oncology• Biology• Physics, 2003. 57(5): p. 1317–1322.CrossRefGoogle Scholar
- 25.Tucker, S.L., H.H. Liu, S. Wang, X. Wei, Z. Liao, R. Komaki, J.D. Cox, and R. Mohan, Dose–volume modeling of the risk of postoperative pulmonary complications among esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. International Journal of Radiation Oncology• Biology• Physics, 2006. 66(3): p. 754–761.CrossRefGoogle Scholar